SWOG clinical trial number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Open
Phase
Abbreviated Title
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Status Notes
This study is open to accrual on December 21, 2021.
Activated
12/21/2021
Research committees
Lung Cancer
Treatment
Carboplatin
Pemetrexed
Ipilimumab
Nivolumab
Paclitaxel
Pembrolizumab
Eligibility Criteria Expand/Collapse
SWOG Cancer Research Network has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for more information and registration procedures.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for more information and registration procedures.
Publication Information Expand/Collapse
2022
Other Clinical Trials
SWOG Clinical Trial Number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
95%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open